Anthony J. Polverino
Directeur/Bestuurslid bij BRAINSTORM CELL THERAPEUTICS INC.
Vermogen: 13 811 $ op 30-04-2024
Actieve functies van Anthony J. Polverino
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Directeur/Bestuurslid | 05-02-2018 | - |
| Independent Dir/Board Member | 05-02-2018 | - |
Loopbaan van Anthony J. Polverino
Eerdere bekende functies van Anthony J. Polverino
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Hoofd Techniek/Wetenschap/O&O | 20-09-2018 | 19-01-2022 |
| KITE PHARMA INC | Hoofd Techniek/Wetenschap/O&O | 01-01-2015 | 01-01-2018 |
| AMGEN INC. | Corporate Officer/Principal | - | - |
Opleiding van Anthony J. Polverino
| University of Adelaide | Undergraduate Degree |
| Flinders University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Australië | 3 |
| Canada | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
